The compound traditional Chinese medicine Qingkailing, which is an ingredient used to treat cerebral ischemia, has been limited to studies concerning single genes or single pathways. Interactions and pharmacological m...The compound traditional Chinese medicine Qingkailing, which is an ingredient used to treat cerebral ischemia, has been limited to studies concerning single genes or single pathways. Interactions and pharmacological mechanisms of the compound ingredients （baicalin and jasminoidin） remain poorly understood. In the present study, baicalin and jasminoidin, as well as the combination, were used to separately treat mouse models of cerebral ischemia, cDNA microarray analyses of 374 cerebral ischemia-related genes were utilized to determine changes in gene-expression profiles. Arraytrack 3.40 and Ingenuity Pathway Analysis （IPA） databases were utilized to analyze changes in gene molecular functions and network path functions. Baicalin or jasminoidin alone effectively reduced infarct area, and the combination resulted in significantly better outcomes. IPA showed inhibited cell apoptosis in the baicalin group and Ca^2＋ channel regulation in the jasminoidin group. The combination of baicalin and jasminoidin activated HTR3A and F5 expression, regulated Ca^2＋ channels, activated kappa light polypeptide gene enhancer inhibitor IKBKG in B cells to control IkB kinase/nuclear factor-kB cascade, suppressed activation of inflammatory cytokine interleukin-6 receptors and activated transduction of guanine-nucleotide- binding protein （G protein） signal. Results suggested that the combination of baicalin and jasminoidin resulted in similar molecular mechanisms to baicalin and jasminoidin alone. However, novel pharmacological actions of compatibility were detected, demonstrating significant protection against cerebral ischemia.展开更多
基金the Postdoctoral Science Foundation of China,No.20090450553
文摘The compound traditional Chinese medicine Qingkailing, which is an ingredient used to treat cerebral ischemia, has been limited to studies concerning single genes or single pathways. Interactions and pharmacological mechanisms of the compound ingredients （baicalin and jasminoidin） remain poorly understood. In the present study, baicalin and jasminoidin, as well as the combination, were used to separately treat mouse models of cerebral ischemia, cDNA microarray analyses of 374 cerebral ischemia-related genes were utilized to determine changes in gene-expression profiles. Arraytrack 3.40 and Ingenuity Pathway Analysis （IPA） databases were utilized to analyze changes in gene molecular functions and network path functions. Baicalin or jasminoidin alone effectively reduced infarct area, and the combination resulted in significantly better outcomes. IPA showed inhibited cell apoptosis in the baicalin group and Ca^2＋ channel regulation in the jasminoidin group. The combination of baicalin and jasminoidin activated HTR3A and F5 expression, regulated Ca^2＋ channels, activated kappa light polypeptide gene enhancer inhibitor IKBKG in B cells to control IkB kinase/nuclear factor-kB cascade, suppressed activation of inflammatory cytokine interleukin-6 receptors and activated transduction of guanine-nucleotide- binding protein （G protein） signal. Results suggested that the combination of baicalin and jasminoidin resulted in similar molecular mechanisms to baicalin and jasminoidin alone. However, novel pharmacological actions of compatibility were detected, demonstrating significant protection against cerebral ischemia.
